Many men with low-risk, localized prostate cancers can safely choose active surveillance or "watchful waiting" instead of undergoing immediate treatment and have better quality of life while reducing health care costs, according to a study by researchers at Dana-Farber Cancer Institute and Massachusetts General Hospital.
[More]
KLAS just released the 2013 Best in KLAS Awards: Medical Equipment & Infrastructure report ranking the best-performing imaging, pharmacy automation and infrastructure vendors in the world.
[More]
Black women with breast cancer are more likely than Hispanic or white women to experience delays in the initiation of chemotherapy or radiation after surgery, finds a new study in Health Services Research.
[More]
External beam radiation treatment has long been manipulated into the unique shape of patients' tumors for personalized cancer care. Technology providing a means of patient-specific radionuclide drug therapies has not been standardized, as it has been limited to software that requires oncologists to manually define the areas of tumors.
[More]
Several years ago, Virginia Commonwealth University Massey Cancer Center became the first center in the United States to test an Israeli-invented device designed to increase the space between the prostate and the rectum in prostate cancer patients undergoing radiation therapy.
[More]
The Cancer Institute of New Jersey is one of 50 sites across the nation to offer a clinical trial known as COMET-2 that examines whether the drug cabozantinib is effective in reducing bone pain in patients with prostate cancer that is no longer responsive to hormone therapy and has spread (metastasized) to other parts of the body.
[More]
Researchers at UCLA's Jonsson Comprehensive Cancer Center led by Dr. Karim Chamie have found that more intense surveillance and treatment of bladder cancer in the first two years after diagnosis could reduce the number of patients whose cancer returns after treatment and lower the disease's death rate. The study was published online ahead of press today in the journal Cancer.
[More]
For the nation's fastest growing population, cancer ranked as the number one leading cause of death among Hispanics, based on a 2012 American Cancer Society report.
[More]
Accuray Incorporated, announced today the first patient has been treated with its new TomoHDA System at Centre Oscar Lambret in Lille, France.
[More]
The American Society for Radiation Oncology (ASTRO) will award Amato J. Giaccia, PhD, Radhe Mohan, PhD, FASTRO, and Prabhakar Tripuraneni, MD, FASTRO, with the Society's highest honor—the ASTRO Gold Medal. The 2013 awardees will receive the ASTRO Gold Medal during the Awards Ceremony on Tuesday, September 24, at ASTRO's 55th Annual Meeting, September 22-25, 2013, at the Georgia World Congress Center in Atlanta.
[More]
Stories often appear in health communication in order to encourage individuals to change behaviors, such as smoking or not wearing sunscreen. A University of Missouri researcher studied how stories influence patients' decision-making when behavior change is not the desired outcome of the health communication.
[More]
A new review by researchers at the University of Maryland School of Medicine highlights a large body of published research demonstrating how modified citrus pectin, works against cancer.
[More]
A multi-institutional team of researchers have pinpointed the genetic traits of the cells that give rise to gliomas - the most common form of malignant brain cancer. The findings, which appear in the journal Cell Reports, provide scientists with rich new potential set of targets to treat the disease.
[More]
Soligenix, Inc., a clinical stage biopharmaceutical company, announced today that its SGX942 development program for the treatment of oral mucositis as a result of radiation and/or chemotherapy treatment in head and neck cancer patients has received "Fast Track" designation from the US Food and Drug Administration.
[More]
A new test may help identify newly diagnosed glioblastoma patients more likely to benefit from bevacizumab (Avastin-), according to new research from The University of Texas MD Anderson Cancer Center.
[More]
Patients with cancer that has spread to their bones are often treated with radiation therapy to reduce pain. But if that treatment doesn't work, or can't be used again, a second, effective option now exists.
[More]
The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan-Kettering Cancer Center research presented on Saturday, June 1, at the 49th annual meeting of the American Society of Clinical Oncology.
[More]
Researchers from Fox Chase Cancer Center and other institutions have completed a phase II clinical trial that may help identify those patients with HPV-positive oropharyngeal cancer who do not require the full radiation dose given in a standard regimen of Intensity-Modulated Radiation Therapy (IMRT). Preliminary findings will be presented by Shanthi Marur, first author on the study and an oncologist at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, at the 49th Annual Meeting of the American Society of Clinical Oncology on Sunday, June 2.
[More]
Many glioblastoma patients treated with bevacizumab (Avastin-) have significant deterioration in neurocognitive function, symptoms and quality of life. Not only that, the changes often predict treatment outcomes, according to new research from The University of Texas MD Anderson Cancer Center.
[More]
Doctors at Washington University School of Medicine in St. Louis have shown that testing cervical tumors before treatment for vulnerability to chemotherapy predicts whether patients will do well or poorly with standard treatment.
[More]